BIOAGE platform identifies key drug targets that will impact aging. The company’s proprietary human aging cohorts have blood samples collected up to 45 years ago, with participant -omics data that is tied to extensive medical follow-up records including detailed future healthspan, lifespan, and disease outcomes. We have built a systems biology and AI platform that leverages these rich datasets to identify the molecular drivers of age-related pathology. Our pipeline of therapies targeting these key pathways will address the significant unmet medical needs of an aging population.
This service is currently only supported on the desktop screens, please, use this service from your desktop or laptop for correct visualization and functionality